{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:24:12Z","timestamp":1788387852781,"version":"build-2803163510"},"reference-count":64,"publisher":"MJH Life Sciences","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,29]]},"abstract":"<jats:p>Multiple myeloma, the second most common hematologic malignancy, accounts for approximately 10% of all blood cancers. Therapeutic advances have transformed multiple myeloma from a uniformly fatal disease into a chronic, manageable condition. Autologous stem cell transplantation (ASCT) remains a cornerstone of frontline treatment, demonstrating superiority in progression-free survival (PFS) and minimal residual disease (MRD) negativity compared with chemotherapy alone or modern induction regimens without transplant. International guidelines continue to recommend ASCT as the standard of care for eligible patients. Maintenance therapy post ASCT further improves PFS and overall survival, although it carries a modestly increased risk of secondary malignancies. Meanwhile, novel immunotherapies, including chimeric antigen receptor T cells and bispecific antibodies, are reshaping treatment strategies, showing strong efficacy in relapsed\/refractory multiple myeloma. Ongoing trials are evaluating their role in frontline settings, with the potential to complement or replace ASCT. The future of multiple myeloma management hinges on precision medicine, using MRD assessment, genomic profiling, and patient-specific risk stratification to guide therapy. As these personalized approaches are integrated alongside established therapies, the goal of achieving long-term remission and potentially a cure becomes increasingly attainable.<\/jats:p>","DOI":"10.46883\/2026.25921059","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T19:04:19Z","timestamp":1771355059000},"page":"34","source":"Crossref","is-referenced-by-count":2,"title":["Autologous Stem Cell Transplantation in Multiple Myeloma: Is It Still the Gold Standard?"],"prefix":"10.46883","volume":"40","author":[{"given":"Taha Kassim","family":"Dohadwal","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04w893s72","id-type":"ROR","asserted-by":"publisher"}],"name":"David Tvildiani Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Ghazal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/001qst305","id-type":"ROR","asserted-by":"publisher"}],"name":"Kalamazoo College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumiya","family":"Nadar","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/020jbrt22","id-type":"ROR","asserted-by":"publisher"}],"name":"Tbilisi State Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riya","family":"Vaishnav","sequence":"additional","affiliation":[{"name":"Medical College Baroda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishan","family":"Paduvagere","sequence":"additional","affiliation":[{"name":"Santa Susana High School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Cortiana","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01111rn36","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Bologna"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandler","family":"Park","sequence":"additional","affiliation":[{"name":"Norton Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Leyfman","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"25947","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"ref0","unstructured":"Albagoush SA, Azevedo AM, Shumway C. Multiple myeloma. In: StatPearls; StatPearls Publishing; 2023. Accessed December 4, 2025. https:\/\/tinyurl.com\/3abuxz5z"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Fairfield H, Falank C, Avery L, Reagan MR. Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci. 2016;1364(1):32-51. doi:10.1111\/nyas.13038","DOI":"10.1111\/nyas.13038"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311-1320. doi:10.1056\/NEJMoa1611750","DOI":"10.1056\/NEJMoa1611750"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Yuan S, Chen Y, Liu H. Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma. Ther Adv Hematol. 2024;15:20406207241237594. doi:10.1177\/20406207241237594","DOI":"10.1177\/20406207241237594"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Parrondo RD, Ailawadhi S, Sher T, Chanan-Khan AA, Roy V. Autologous stem-cell transplantation for multiple myeloma in the era of novel therapies. JCO Oncol Pract. 2020;16(2):56-66. doi:10.1200\/JOP.19.00335","DOI":"10.1200\/JOP.19.00335"},{"key":"ref5","unstructured":"MedNews Week YouTube page. MedNews Week Keynote Conference (Live Stream) - Dr. Muzaffar Qazilbash (MD Anderson Cancer Center). Accessed May 12, 2025. https:\/\/tinyurl.com\/3u68fe7m"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Mor\u00e8 S, Corvatta L, Manieri VM, et al. Autologous stem cell transplantation in multiple myeloma: where are we and where do we want to go? Cells. 2022;11(4):606. doi:10.3390\/cells11040606","DOI":"10.3390\/cells11040606"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Ebraheem M, Kumar SK, Dispenzieri A, et al. Deepening responses after upfront autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in the era of novel agent induction therapy. Transpl Cell Ther. 2022;28(11):760.e1-5. Accessed May 27, 2025. doi:10.1016\/j.jtct.2022.07.030","DOI":"10.1016\/j.jtct.2022.07.030"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"de Tute RM, Pawlyn C, Cairns DA, et al. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. J Clin Oncol. 2022;40(25):2889-2900. doi:10.1200\/JCO.21.02228","DOI":"10.1200\/JCO.21.02228"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"de Tute RM, Pawlyn C, Cairns DA, et al. Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk. J Clin Oncol. 2022;40(25):2889-2900. doi:10.1200\/JCO.21.02228","DOI":"10.1200\/JCO.21.02228"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"van de Velde H, Londhe A, Ataman O, et al. Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents. Eur J Haematol. 2017;98(3):269-279. doi:10.1111\/ejh.12829","DOI":"10.1111\/ejh.12829"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Nijhof IS, van de Donk NW, Zweegman S, Lokhorst HM. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs. 2018;78(1):19-37. doi:10.1007\/s40265-017-0841-y","DOI":"10.1007\/s40265-017-0841-y"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Richardson PG, Jacobus SJ, Weller EA, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387(2):132-147. doi:10.1056\/NEJMoa2204925","DOI":"10.1056\/NEJMoa2204925"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311-1320. doi:10.1056\/nejmoa1611750","DOI":"10.1056\/NEJMoa1611750"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Gay F, Musto P, Rota-Scalabrini D, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021;22(12):1705-1720. doi:10.1016\/S1470-2045(21)00535-0","DOI":"10.1016\/S1470-2045(21)00535-0"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7(6):e456-e468. doi:10.1016\/S2352-3026(20)30099-5","DOI":"10.1016\/S2352-3026(20)30099-5"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Stadtmauer EA, Pasquini MC, Blackwell B, et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol. 2019;37(7):589-597. doi:10.1200\/JCO.18.00685","DOI":"10.1200\/JCO.18.00685"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Mellqvist UH, Gimsing P, Hjertner \u00d8, et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood. 2013;121(23):4647-4654. doi:10.1182\/blood-2012-11-464503","DOI":"10.1182\/blood-2012-11-464503"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Fazio F, Gherardini M, Rossi E, et al. Long-term survival with multiple myeloma: an Italian experience. Cancers. 2025;17(3):354\u20134. doi:10.3390\/cancers17030354","DOI":"10.3390\/cancers17030354"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"C\u00f4t\u00e9 J, LeBlanc R, Mian H, et al. Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database. Blood Cancer J. 2023;13(1). doi:10.1038\/s41408-023-00905-8","DOI":"10.1038\/s41408-023-00905-8"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Bergin K, Wellard C, Augustson B, et al. Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). Bone Marrow Transplant. 2021;56(10):2533-2543. doi:10.1038\/s41409-021-01308-8","DOI":"10.1038\/s41409-021-01308-8"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311-1320. doi:10.1056\/NEJMoa1611750","DOI":"10.1056\/NEJMoa1611750"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Dulka B, Bone RN, Jeune-Smith Y, Baljevic M, Feinberg BA. The DETERMINATION trial impact on upfront (vs delayed) autologous stem cell transplantation for transplant-eligible newly diagnosed multiple myeloma. Blood. 2022;140(suppl 1):10958-10959. doi:10.1182\/blood-2022-166490","DOI":"10.1182\/blood-2022-166490"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Mian O, Puts M, McCurdy A, et al. Decision-making factors for an autologous stem cell transplant for older adults with newly diagnosed multiple myeloma: a qualitative analysis. Front Oncol. 2023;12:974038. doi:10.3389\/fonc.2022.974038","DOI":"10.3389\/fonc.2022.974038"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Hashmi H, Davis JA, Abdallah AO. \u2018A stitch in time saves nine\u2019: early stem cell transplant continues to improve outcomes in patients with newly diagnosed multiple myeloma. Expert Rev Hematol. 2023;16(8):561-563. doi:10.1080\/17474086.2023.2227789","DOI":"10.1080\/17474086.2023.2227789"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Chakraborty R, Hamilton BK, Hashmi SK, Kumar SK, Majhail NS. Health-related quality of life after autologous stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2018;24(8):1546-1553. doi:10.1016\/j.bbmt.2018.03.027","DOI":"10.1016\/j.bbmt.2018.03.027"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Blackburn L, Mansour A, Zhao Q, Cottini F, Khan A, Bumma N, et al. Real world predictors, timing, and outcomes of autologous stem cell transplantation in patients with multiple myeloma. Hemato. 2024;5(4):407-419. doi:10.3390\/hemato5040030","DOI":"10.3390\/hemato5040030"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol. 2002;3(7):687-694. doi:10.1038\/ni813","DOI":"10.1038\/ni813"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Rettig MP, Ramirez P, Nervi B, DiPersio JF. CXCR4 and mobilization of hematopoietic precursors. Methods Enzymol. 2009;460:57-90. doi:10.1016\/S0076-6879(09)05203-3","DOI":"10.1016\/S0076-6879(09)05203-3"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Wei X, Wei Y. Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments. Ann Hematol. 2023;102(5):995-1009. doi:10.1007\/s00277-023-05170-0","DOI":"10.1007\/s00277-023-05170-0"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720-5726. doi:10.1182\/blood-2008-08-174946","DOI":"10.1182\/blood-2008-08-174946"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Van de Wyngaert Z, Nerich V, Fouquet G, et al. Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma. Bone Marrow Transplant. 2020;55(12):2254-2260. doi:10.1038\/s41409-020-0940-3","DOI":"10.1038\/s41409-020-0940-3"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Gopal AK, Karami M, Mayor J, et al. The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells. J Clin Apher. 2012;27(2):81-87. doi:10.1002\/jca.21206","DOI":"10.1002\/jca.21206"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Wang L, Xiang H, Yan Y, et al. Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis. Ann Hematol. 2021;100(2):563-573. doi:10.1007\/s00277-020-04376-w","DOI":"10.1007\/s00277-020-04376-w"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Narayanasami U, Kanteti R, Morelli J, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood. 2001;98(7):2059-2064. doi:10.1182\/blood.v98.7.2059","DOI":"10.1182\/blood.V98.7.2059"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Dill V, Bl\u00fcm P, Lindemann A, et al. Comparison of two autologous hematopoietic stem cell mobilization strategies in patients with multiple myeloma: CE plus G-CSF versus G-CSF only: a single-center retrospective analysis. Transfusion. 2024;64(5):871-880. doi:10.1111\/trf.17829","DOI":"10.1111\/trf.17829"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Giralt S. 200 mg\/m(2) melphalan--the gold standard for multiple myeloma. Nat Rev Clin Oncol. 2010;7(9):490-491. doi:10.1038\/nrclinonc.2010.104","DOI":"10.1038\/nrclinonc.2010.104"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Lea JC, Aziz M, Simmons GL. Evaluation of high-dose melphalan toxicity by age in patients undergoing autologous stem cell transplant for multiple myeloma. Biol Blood Marrow Transplant. 2019;25(suppl 3):S281. doi:10.1016\/j.bbmt.2018.12.351","DOI":"10.1016\/j.bbmt.2018.12.351"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Anagnostopoulos A, Aleman A, Ayers G, et al. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer. 2004;100(12):2607-2612. doi:10.1002\/cncr.20294","DOI":"10.1002\/cncr.20294"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Bashir Q, Thall PF, Milton DR, et al. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019;6(5):e266-e275. doi:10.1016\/S2352-3026(19)30023-7","DOI":"10.1016\/S2352-3026(19)30023-7"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Mateos MV, Gonz\u00e1lez-Calle V. Lenalidomide maintenance based on a genetic profile. Blood. 2023;141(14):1649-1650. doi:10.1182\/blood.2022019352","DOI":"10.1182\/blood.2022019352"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(1):57-73. doi:10.1016\/S1470-2045(18)30687-9","DOI":"10.1016\/S1470-2045(18)30687-9"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279-3289. doi:10.1200\/JCO.2017.72.6679","DOI":"10.1200\/JCO.2017.72.6679"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Sperling AS, Guerra VA, Kennedy JA, et al. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood. 2022;140(16):1753-1763. doi:10.1182\/blood.2021014956","DOI":"10.1182\/blood.2021014956"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Laharwal MM, Snyder J, Khaliq A, Rahman RL, Atrash S, Mushtaq MU, et al. Use of doublet maintenance (bortezomib-lenalidomide) vs monotherapy lenalidomide as maintenance therapy post-transplant of patients with high-risk cytogenetics myeloma. Blood. 2024;144(suppl 1):7017. doi:10.1182\/blood-2024-201907","DOI":"10.1182\/blood-2024-201907"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Gay F, Schjesvold F, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019;393(10168):253-264. doi:10.1016\/S0140-6736(18)33003-4","DOI":"10.1016\/S0140-6736(18)33003-4"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936-945. doi:10.1182\/blood.2020005288","DOI":"10.1182\/blood.2020005288"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Ho M, Zanwar S, Kapoor P, et al. The effect of duration of lenalidomide maintenance and outcomes of different salvage regimens in patients with multiple myeloma (MM). Blood Cancer J. 2021;11(9):158. doi:10.1038\/s41408-021-00548-7","DOI":"10.1038\/s41408-021-00548-7"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Derman BA, Major A, Cooperrider J, et al. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024;14(1):170. Published 2024 Oct 7. doi:10.1038\/s41408-024-01156-x","DOI":"10.1038\/s41408-024-01156-x"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Patel DA, Gopalakrishnan R, Engelhardt BG, et al. Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma. Bone Marrow Transplant. 2020;55(6):1137-1146. doi:10.1038\/s41409-020-0791-y","DOI":"10.1038\/s41409-020-0791-y"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Swan D, Madduri D, Hocking J. CAR-T cell therapy in multiple myeloma: current status and future challenges. Blood Cancer J. 2024;14(1):206. doi:10.1038\/s41408-024-01191-8","DOI":"10.1038\/s41408-024-01191-8"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495-505. doi:10.1056\/NEJMoa2203478","DOI":"10.1056\/NEJMoa2203478"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Qazilbash MH, Saini NY, Cha SC, et al. A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. Blood. 2022;139(9):1289-1301. doi:10.1182\/blood.2020008493","DOI":"10.1182\/blood.2020008493"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Boccadoro M, San-Miguel J, Suzuki K, et al. DVRd followed by ciltacabtagene autoleucel versus DVRd followed by ASCT in patients with newly diagnosed multiple myeloma who are transplant eligible: a randomized phase 3 study (EMagine\/CARTITUDE-6). Blood. 2022;140(suppl 1):4630-4632. doi:10.1182\/blood-2022-157021","DOI":"10.1182\/blood-2022-157021"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Berdeja JG, Truppel-Hartmann A, et al. KarMMa-4: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma. J Clin Oncol. 2021;39(suppl 15):TPS8053. doi:10.1200\/JCO.2021.39.15_suppl.TPS8053","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8053"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Nasiri F, Asaadi Y, Mirzadeh F, et al. Updates on CAR T cell therapy in multiple myeloma. Biomark Res. 2024;12(1):102. doi:10.1186\/s40364-024-00634-5","DOI":"10.1186\/s40364-024-00634-5"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Attal M, Harousseau JL. Role of autologous stem-cell transplantation in multiple myeloma. Best Pract Res Clin Haematol. 2007;20(4):747-759. doi:10.1016\/j.beha.2007.09.006","DOI":"10.1016\/j.beha.2007.09.006"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410-427. doi:10.1016\/S0140-6736(21)00135-5","DOI":"10.1016\/S0140-6736(21)00135-5"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279-3289. doi:10.1200\/JCO.2017.72.6679","DOI":"10.1200\/JCO.2017.72.6679"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266-2275. doi:10.1038\/s41375-019-0435-7","DOI":"10.1038\/s41375-019-0435-7"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Garfall AL. Updated analysis of EMN02 demonstrated overall survival benefit to early ASCT for multiple myeloma. Blood Cancer J. 2025;15(1):1. doi:10.1038\/s41408-024-01198-1","DOI":"10.1038\/s41408-024-01198-1"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Leypoldt L, Tichy D, Besemer B, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. J Clin Oncol. 2024;42(1):26-37. doi:10.1200\/JCO.23.01696","DOI":"10.1200\/JCO.23.01696"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Anderson LD, Dhakal B, Jain T, et al. Chimeric antigen receptor T-cell therapy for myeloma: where are we now and what is needed to move CAR T-cells forward to earlier lines of therapy?. Expert panel opinion from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2024;30(1):17-37. doi:10.1016\/j.jtct.2023.10.022","DOI":"10.1016\/j.jtct.2023.10.022"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Al-Odat OS, Nelson E, Budak-Alpdogan T, Jonnalagadda SC, Desai D, Pandey MK. Discovering potential in non-cancer medications: a promising breakthrough for multiple myeloma patients. Cancers (Basel). 2024;16(13):2381. doi:10.3390\/cancers16132381","DOI":"10.3390\/cancers16132381"}],"container-title":["ONCOLOGY"],"original-title":[],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T19:04:24Z","timestamp":1771355064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cancernetwork.com\/view\/autologous-stem-cell-transplantation-in-multiple-myeloma-is-it-still-the-gold-standard-"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,10]]},"published-print":{"date-parts":[[2026,1,29]]}},"URL":"https:\/\/doi.org\/10.46883\/2026.25921059","relation":{},"ISSN":["0890-9091","2767-7389"],"issn-type":[{"value":"0890-9091","type":"print"},{"value":"2767-7389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}